Dashenlin Pharm Grp Co Ltd (603233) - Net Assets
Based on the latest financial reports, Dashenlin Pharm Grp Co Ltd (603233) has net assets worth CN¥9.18 Billion CNY (≈ $1.34 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥26.83 Billion ≈ $3.93 Billion USD) and total liabilities (CN¥17.65 Billion ≈ $2.58 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Dashenlin Pharm Grp Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥9.18 Billion |
| % of Total Assets | 34.23% |
| Annual Growth Rate | 27.16% |
| 5-Year Change | 45.92% |
| 10-Year Change | 545.37% |
| Growth Volatility | 31.54 |
Dashenlin Pharm Grp Co Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Dashenlin Pharm Grp Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 603233 company net worth.
Annual Net Assets for Dashenlin Pharm Grp Co Ltd (2012–2025)
The table below shows the annual net assets of Dashenlin Pharm Grp Co Ltd from 2012 to 2025. Also explore net asset growth rate of Dashenlin Pharm Grp Co Ltd to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥8.66 Billion ≈ $1.27 Billion |
+6.43% |
| 2024-12-31 | CN¥8.14 Billion ≈ $1.19 Billion |
+2.59% |
| 2023-12-31 | CN¥7.93 Billion ≈ $1.16 Billion |
+15.57% |
| 2022-12-31 | CN¥6.86 Billion ≈ $1.00 Billion |
+15.64% |
| 2021-12-31 | CN¥5.94 Billion ≈ $868.61 Million |
+6.51% |
| 2020-12-31 | CN¥5.57 Billion ≈ $815.49 Million |
+28.65% |
| 2019-12-31 | CN¥4.33 Billion ≈ $633.86 Million |
+40.33% |
| 2018-12-31 | CN¥3.09 Billion ≈ $451.68 Million |
+10.13% |
| 2017-12-31 | CN¥2.80 Billion ≈ $410.12 Million |
+108.83% |
| 2016-12-31 | CN¥1.34 Billion ≈ $196.39 Million |
+31.42% |
| 2015-12-31 | CN¥1.02 Billion ≈ $149.43 Million |
+77.65% |
| 2014-12-31 | CN¥574.85 Million ≈ $84.12 Million |
-2.56% |
| 2013-12-31 | CN¥589.93 Million ≈ $86.32 Million |
+54.79% |
| 2012-12-31 | CN¥381.11 Million ≈ $55.77 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Dashenlin Pharm Grp Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3090.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.31 Billion | 58.51% |
| Other Components | CN¥3.06 Billion | 41.49% |
| Total Equity | CN¥7.37 Billion | 100.00% |
Dashenlin Pharm Grp Co Ltd Competitors by Market Cap
The table below lists competitors of Dashenlin Pharm Grp Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kemira Oyj
HE:KEMIRA
|
$2.96 Billion |
|
SKC Co. Ltd
KO:011790
|
$2.96 Billion |
|
Green Brick Partners Inc
NYSE:GRBK
|
$2.96 Billion |
|
Solvay SA
BR:SOLB
|
$2.96 Billion |
|
Sportradar Group AG
NASDAQ:SRAD
|
$2.96 Billion |
|
Fortior Technology (Shenzhen) Co. Ltd. A
SHG:688279
|
$2.96 Billion |
|
Jumbo S.A.
AT:BELA
|
$2.96 Billion |
|
Provident Financial Services Inc
NYSE:PFS
|
$2.95 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dashenlin Pharm Grp Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,897,244,933 to 7,367,779,875, a change of 470,534,942 (6.8%).
- Net income of 1,235,246,215 contributed positively to equity growth.
- Dividend payments of 782,100,078 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.24 Billion | +16.77% |
| Dividends Paid | CN¥782.10 Million | -10.62% |
| Other Changes | CN¥17.39 Million | +0.24% |
| Total Change | CN¥- | 6.82% |
Book Value vs Market Value Analysis
This analysis compares Dashenlin Pharm Grp Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.74x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 27.37x to 2.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.65 | CN¥17.75 | x |
| 2013-12-31 | CN¥0.72 | CN¥17.75 | x |
| 2014-12-31 | CN¥0.68 | CN¥17.75 | x |
| 2015-12-31 | CN¥1.18 | CN¥17.75 | x |
| 2016-12-31 | CN¥1.35 | CN¥17.75 | x |
| 2017-12-31 | CN¥2.71 | CN¥17.75 | x |
| 2018-12-31 | CN¥2.81 | CN¥17.75 | x |
| 2019-12-31 | CN¥3.20 | CN¥17.75 | x |
| 2020-12-31 | CN¥4.75 | CN¥17.75 | x |
| 2021-12-31 | CN¥4.82 | CN¥17.75 | x |
| 2022-12-31 | CN¥5.47 | CN¥17.75 | x |
| 2023-12-31 | CN¥6.03 | CN¥17.75 | x |
| 2024-12-31 | CN¥6.11 | CN¥17.75 | x |
| 2025-12-31 | CN¥6.47 | CN¥17.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dashenlin Pharm Grp Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.77%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.49%
- • Asset Turnover: 1.04x
- • Equity Multiplier: 3.59x
- Recent ROE (16.77%) is below the historical average (25.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 45.45% | 4.59% | 3.26x | 3.04x | CN¥116.36 Million |
| 2013 | 37.55% | 5.33% | 2.21x | 3.20x | CN¥144.82 Million |
| 2014 | 53.08% | 5.84% | 1.92x | 4.73x | CN¥215.49 Million |
| 2015 | 38.72% | 7.51% | 1.98x | 2.60x | CN¥293.32 Million |
| 2016 | 32.65% | 6.86% | 1.75x | 2.72x | CN¥298.45 Million |
| 2017 | 17.25% | 6.40% | 1.27x | 2.12x | CN¥199.68 Million |
| 2018 | 17.50% | 6.00% | 1.36x | 2.15x | CN¥227.82 Million |
| 2019 | 16.57% | 6.31% | 1.28x | 2.05x | CN¥278.67 Million |
| 2020 | 19.73% | 7.28% | 1.18x | 2.29x | CN¥523.70 Million |
| 2021 | 14.44% | 4.72% | 0.97x | 3.16x | CN¥243.37 Million |
| 2022 | 16.67% | 4.87% | 1.02x | 3.36x | CN¥414.54 Million |
| 2023 | 17.09% | 4.76% | 1.02x | 3.54x | CN¥484.11 Million |
| 2024 | 13.26% | 3.45% | 1.00x | 3.83x | CN¥225.03 Million |
| 2025 | 16.77% | 4.49% | 1.04x | 3.59x | CN¥498.47 Million |
Industry Comparison
This section compares Dashenlin Pharm Grp Co Ltd's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $1,374,033,604
- Average return on equity (ROE) among peers: 10.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dashenlin Pharm Grp Co Ltd (603233) | CN¥9.18 Billion | 45.45% | 1.92x | $2.96 Billion |
| Cachet Pharmaceutical Co Ltd (002462) | $2.94 Billion | 7.60% | 1.51x | $529.31 Million |
| Yunnan Hongxiang Yixintang (002727) | $2.08 Billion | 14.28% | 0.41x | $939.19 Million |
| Luyan Pharma Co Ltd (002788) | $649.30 Million | 16.84% | 4.10x | $639.02 Million |
| Ji Yao Holding Group Co Ltd (300108) | $361.01 Million | 7.57% | 0.06x | $20.47 Million |
| ShuYu Civilian Pharmacy Corp. Ltd. (301017) | $1.33 Billion | 8.38% | 0.84x | $768.62 Million |
| Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) | $1.68 Billion | 4.07% | 0.78x | $314.40 Million |
| Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) | $2.06 Billion | 6.68% | 1.34x | $910.79 Million |
| Shanghai No1 Pharmacy Co Ltd (600833) | $186.74 Million | 13.27% | 2.88x | $354.85 Million |
| Laobaixing Pharmacy (603883) | $1.09 Billion | 18.64% | 1.33x | $1.44 Billion |
About Dashenlin Pharm Grp Co Ltd
DaShenLin Pharmaceutical Group Co., Ltd. engages in the manufacture, distribution, and retail of pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and tonic herbs, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.